

C Warren Olanow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9588405/publications.pdf>

Version: 2024-02-01

105
papers

23,446
citations

24978

57
h-index

31759

101
g-index

150
all docs

150
docs citations

150
times ranked

19069
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity. <i>Movement Disorders</i> , 2022, 37, 6-15.	2.2	21
2	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 177-186.	1.5	33
3	A New Approach to the Development of Disease-Modifying Therapies for PD ; Fighting Another Pandemic. <i>Movement Disorders</i> , 2021, 36, 59-63.	2.2	13
4	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2244-2253.	2.2	16
5	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 Year Data from the Open-Label BeyOND Study. <i>Movement Disorders</i> , 2021, 36, 2687-2692.	2.2	20
6	Dose optimization of apomorphine sublingual film for treating OFF episodes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 27-30.	1.1	8
7	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	4.9	80
8	Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. <i>Journal of Huntington's Disease</i> , 2020, 9, 371-380.	0.9	17
9	Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities. <i>Movement Disorders</i> , 2020, 35, 1731-1744.	2.2	47
10	Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. <i>Brain</i> , 2020, 143, 960-975.	3.7	56
11	Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020, 35, 1055-1061.	2.2	24
12	Temporal evolution of microglia and α -synuclein accumulation following foetal grafting in Parkinson's disease. <i>Brain</i> , 2019, 142, 1690-1700.	3.7	75
13	<i>Movement Disorders</i> Journal: Yesterday, Today, Tomorrow, and Always. <i>Movement Disorders</i> , 2019, 34, 1814-1816.	2.2	1
14	Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. <i>Movement Disorders</i> , 2019, 34, 425-429.	2.2	11
15	Levodopa: A new look at an old friend. <i>Movement Disorders</i> , 2018, 33, 859-866.	2.2	89
16	Adverse event reporting in clinical trials in Parkinson's Disease: Time for change. <i>Movement Disorders</i> , 2018, 33, 1685-1687.	2.2	1
17	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
18	Targeting α -Synuclein as a therapy for Parkinson's disease: The battle begins. <i>Movement Disorders</i> , 2017, 32, 203-207.	2.2	26

#	ARTICLE	IF	CITATIONS
19	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>P</scp>arkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57.	2.8	72
20	Translating scientific advances into disease-modifying therapies for Parkinson's Disease. <i>Experimental Neurology</i> , 2017, 298, 135-136.	2.0	1
21	Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. <i>European Polymer Journal</i> , 2017, 88, 524-552.	2.6	124
22	Eldad Melamed 1942-2015: Ave atque-A memorial. <i>Movement Disorders</i> , 2016, 31, 39-40.	2.2	0
23	Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1366-1372.	2.2	67
24	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1489-1496.	2.2	45
25	Fetal grafts for Parkinson's disease: Decades in the making. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6332-6334.	3.3	8
26	Trophic factors for Parkinson's disease: To live or let die. <i>Movement Disorders</i> , 2015, 30, 1715-1724.	2.2	55
27	Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp>arkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	2.8	224
28	Advances in clinical trials for movement disorders. <i>Movement Disorders</i> , 2015, 30, 1580-1587.	2.2	8
29	Targeting α -synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. <i>Lancet Neurology</i> , The, 2015, 14, 855-866.	4.9	393
30	Levodopa: Effect on cell death and the natural history of Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 37-44.	2.2	83
31	Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research Awardees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17693-17695.	3.3	2
32	Gene therapy for Parkinson disease – a hope, or a dream?. <i>Nature Reviews Neurology</i> , 2014, 10, 186-187.	4.9	12
33	Do prions cause Parkinson disease?: The evidence accumulates. <i>Annals of Neurology</i> , 2014, 75, 331-333.	2.8	34
34	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology</i> , The, 2014, 13, 141-149.	4.9	547
35	Initiating levodopa therapy for Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 430-430.	2.2	5
36	Peripheral alpha-synuclein and Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 963-966.	2.2	32

#	ARTICLE	IF	CITATIONS
37	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2014, 13, 767-776.	4.9	120
38	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. <i>Lancet</i> , The, 2014, 384, 545-555.	6.3	336
39	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1064-1071.	2.2	374
40	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. <i>Brain</i> , 2013, 136, 2419-2431.	3.7	965
41	Therapeutic prospects for Parkinson disease. <i>Annals of Neurology</i> , 2013, 74, 337-347.	2.8	122
42	Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?. <i>Movement Disorders</i> , 2013, 28, 31-40.	2.2	320
43	The Vatican Meeting on Neuroprotection for Parkinson's Disease. <i>Movement Disorders</i> , 2013, 28, 1-2.	2.2	26
44	The state of the journal 2013. <i>Movement Disorders</i> , 2013, 28, 259-260.	2.2	0
45	The significance of defining preclinical or prodromal Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 666-669.	2.2	69
46	Milestones in movement disorders clinical trials: Advances and landmark studies. <i>Movement Disorders</i> , 2011, 26, 1003-1014.	2.2	16
47	The <i>Movement Disorders</i> journal-Then and now. <i>Movement Disorders</i> , 2011, 26, 935-936.	2.2	0
48	Parkinson's disease, proteins, and prions: Milestones. <i>Movement Disorders</i> , 2011, 26, 1056-1071.	2.2	36
49	New Sections for <i>Movement Disorders</i> . <i>Movement Disorders</i> , 2011, 26, 2179-2179.	2.2	0
50	Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 1164-1172.	4.9	589
51	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	2.8	330
52	The baton is passed. <i>Movement Disorders</i> , 2010, 25, 1-1.	2.2	5
53	Defining disease-modifying therapies for PD: A road map for moving forward. <i>Movement Disorders</i> , 2010, 25, 1774-1779.	2.2	31
54	The delayed-start study in Parkinson disease. <i>Neurology</i> , 2010, 74, 1149-1150.	1.5	21

#	ARTICLE	IF	CITATIONS
55	The scientific and clinical basis for the treatment of Parkinson disease (2009). <i>Neurology</i> , 2009, 72, S1-136.	1.5	685
56	Is Parkinson's disease a prion disorder?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12571-12572.	3.3	242
57	Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. <i>Neurology</i> , 2009, 72, S59-64.	1.5	57
58	Reply to Montgomery. <i>Annals of Neurology</i> , 2009, 65, 618-619.	2.8	5
59	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596.	2.8	80
60	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video-based analysis. <i>Movement Disorders</i> , 2009, 24, 336-343.	2.2	84
61	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	13.9	830
62	Levodopa therapy for Parkinson's disease: Challenges and future prospects. <i>Movement Disorders</i> , 2008, 23, S495-S496.	2.2	14
63	Levodopa/dopamine replacement strategies in Parkinson's disease-Future directions. <i>Movement Disorders</i> , 2008, 23, S613-S622.	2.2	52
64	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201.	2.2	162
65	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	2.2	4,796
66	Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. <i>Nature Medicine</i> , 2008, 14, 504-506.	15.2	1,472
67	The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration. , 2008, , 1-23.		0
68	Why have we failed to achieve neuroprotection in Parkinson's disease?. <i>Annals of Neurology</i> , 2008, 64, S101-S110.	2.8	125
69	Tolcapone. <i>Clinical Neuropharmacology</i> , 2007, 30, 287-294.	0.2	83
70	The pathogenesis of cell death in Parkinson's disease – 2007. <i>Movement Disorders</i> , 2007, 22, S335-S342.	2.2	191
71	Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 382-392.	2.7	117
72	Movement disorders: a step in the right direction. <i>Lancet Neurology</i> , The, 2006, 5, 3-5.	4.9	5

#	ARTICLE	IF	CITATIONS
73	Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. <i>Lancet Neurology</i> , The, 2006, 5, 677-687.	4.9	461
74	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2006, 5, 1013-1020.	4.9	167
75	Ubiquitinâ€“proteasome system and Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1806-1823.	2.2	175
76	Rationale for considering that propargylamines might be neuroprotective in Parkinsonâ€™s disease. <i>Neurology</i> , 2006, 66, S69-79.	1.5	67
77	A Model-Based Approach for Assessing Parkinsonian Gait and Effects of Levodopa and Deep Brain Stimulation. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2006, , .	0.5	0
78	Reply: Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2005, 20, 643-644.	2.2	7
79	Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy. <i>Movement Disorders</i> , 2005, 20, S3-S10.	2.2	55
80	Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 905-10.	4.9	206
81	Levodopa and the Progression of Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2498-2508.	13.9	1,649
82	Lewy-body formation is an aggresome-related process: a hypothesis. <i>Lancet Neurology</i> , The, 2004, 3, 496-503.	4.9	278
83	The Scientific Basis for the Current Treatment of Parkinson's Disease. <i>Annual Review of Medicine</i> , 2004, 55, 41-60.	5.0	165
84	Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2004, 19, 997-1005.	2.2	331
85	Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study). <i>Clinical Neuropharmacology</i> , 2004, 27, 58-62.	0.2	161
86	COMT inhibitors in Parkinsonâ€™s disease. <i>Neurology</i> , 2004, 62, S72-81.	1.5	70
87	Dietary vitamin E and Parkinson's disease: something to chew on. <i>Lancet Neurology</i> , The, 2003, 2, 74.	4.9	15
88	A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. <i>Annals of Neurology</i> , 2003, 54, 403-414.	2.8	1,450
89	Present and future directions in the management of motor complications in patients with advanced PD. <i>Neurology</i> , 2003, 61, S24-33.	1.5	17
90	Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. <i>Brain</i> , 2002, 125, 2058-2066.	3.7	145

#	ARTICLE	IF	CITATIONS
91	Glial Cells Mediate Toxicity in Glutathione-Depleted Mesencephalic Cultures. <i>Journal of Neurochemistry</i> , 2002, 73, 112-119.	2.1	46
92	The role of dopamine agonists in the treatment of early Parkinson's disease. <i>Neurology</i> , 2002, 58, S33-41.	1.5	32
93	Failure of the ubiquitin-proteasome system in Parkinson's disease. <i>Nature Reviews Neuroscience</i> , 2001, 2, 589-594.	4.9	490
94	Waking up to sleep episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2000, 15, 212-215.	2.2	163
95	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 485-489.	2.2	60
96	Pathophysiology of the basal ganglia in Parkinson's disease. <i>Trends in Neurosciences</i> , 2000, 23, S8-S19.	4.2	702
97	Parkinsonism associated with Sjögren's syndrome: Three cases and a review of the literature. <i>Movement Disorders</i> , 1999, 14, 262-268.	2.2	51
98	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 383-393.	2.2	271
99	Understanding cell death in parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, S72-84.	2.8	605
100	Subthalamic nucleus-mediated excitotoxicity in parkinson's disease: A target for neuroprotection. <i>Annals of Neurology</i> , 1998, 44, S175-88.	2.8	344
101	Dopamine agonists and neuroprotection in parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, S167-74.	2.8	108
102	The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. <i>Annals of Neurology</i> , 1998, 44, S189-96.	2.8	65
103	Fetal Grafting for Parkinson's Disease: Expression of Immune Markers in Two Patients with Functional Fetal Nigral Implants. <i>Cell Transplantation</i> , 1997, 6, 213-219.	1.2	107
104	Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor-Mediated Toxicity In Vitro. <i>Journal of Neurochemistry</i> , 1997, 68, 33-39.	2.1	89
105	Desmethylselegiline, a Metabolite of Selegiline [Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro. <i>Journal of Neurochemistry</i> , 1997, 68, 434-436.	2.1	61